News-ScinoPharm Taiwan, Ltd.

17

Aug 2026

Performance

ScinoPharm Strengthens Three Core Business Pillars and Continues to Optimize Capacity Allocation

ScinoPharm Taiwan, Ltd. (TWSE: 1789) held its online investor conference today, reporting consolidated revenue of US$42.3 million and NT$1,338 million for the first half of 2026. In its API business, several core products supported gross margin performance through product portfolio optimization and continued cost improvements. However, profitability was affected by slower sales of customers’ products, adjustments to production schedules and supply arrangements, as well as operating shortfalls from an investee company. In the second half of the year, ScinoPharm will continue to strengthen its three core business pillars and optimize capacity allocation to support revenue growth.

20

May 2026

ScinoPharm Taiwan Focuses on Metabolic Syndrome Awareness by Promoting Balanced Plant-Based Meals for Employees

ScinoPharm Taiwan has long focused on therapeutic areas including oncology, hematology, central nervous system disorders, and metabolic diseases, while actively advancing the development of GLP-1 related APIs and Drug Products. In parallel with its commitment to pharmaceutical innovation, the company also places strong emphasis on employee wellness and disease prevention, encouraging colleagues to pay greater attention to their personal health through healthier daily habits.

Centered on the concept of “starting change from the dining table,” ScinoPharm Taiwan optimized its employee cafeteria menu by increasing the proportion of fruits and vegetables, making it easier for employees to adopt balanced dietary habits in their everyday lives. In addition, plant-based foods generally generate lower carbon emissions than animal-based products. Choosing locally sourced fruits and vegetables can further reduce transportation distances, logistics-related emissions, and food storage energy consumption, creating additional environmental benefits and contributing to broader sustainability goals.

As metabolic syndrome and chronic diseases continue to affect younger populations, enhancing health awareness and establishing proper dietary and lifestyle habits have become increasingly important for society as a whole. Through this collaboration, employees are not only encouraged to actively practice healthier behaviors themselves, but also to share concepts of healthy eating and health management with their families and social circles, gradually expanding the positive impact beyond the workplace into households and local communities.

19

Mar 2026

Performance

ScinoPharm Taiwan Actively Responds to Government Pharmaceutical Policy, Strengthening Local Supply Chain Resilience

ScinoPharm Taiwan (TWSE: 1789) held its investor conference today to present its 2025 operating results and business progress. Consolidated revenue for the year reached NT$3.163 billion, with net profit after tax of NT$137 million and earnings per share (EPS) of NT$0.17. Through ongoing product mix optimization and cost control, the Company maintained a stable gross margin.

21

Jan 2026

Performance

ScinoPharm Taiwan Announces Approval of Bortezomib Injection for Multiple Myeloma Treatment in Taiwan, Strengthening Domestic Pharmaceutical Supply Chain Resilience

ScinoPharm Taiwan announced that it has successfully obtained marketing approval from the Taiwan Food and Drug Administration (TFDA) for Bortezomib, a treatment for Multiple Myeloma. Following the U.S. FDA approval secured in 2023, the newly granted Taiwan approval marks another significant milestone for the company. This achievement not only highlights ScinoPharm Taiwan’s decades-long expertise in oncology drug development, but also demonstrates its concrete response to the government’s policy to strengthen pharmaceutical supply chain resilience. ScinoPharm Taiwan is currently actively pursuing National Health Insurance reimbursement approval, with the goal of benefiting more patients in Taiwan and firmly anchoring internationally recognized critical manufacturing technologies and high-quality medicines within the local healthcare system.

05

Jan 2026

Performance

ScinoPharm Secures U.S. FDA Approval for Glatiramer Acetate Injection for the Treatment of Multiple Sclerosis

ScinoPharm Taiwan (TWSE: 1789) today announced a landmark achievement in the global pharmaceutical landscape, securing U.S. Food and Drug Administration (FDA) approval for Glatiramer Acetate Injection, a treatment for Multiple Sclerosis (MS), making it the only pharmaceutical company in Taiwan to achieve this historic milestone. This achievement underscores ScinoPharm’s leadership in complex generics and highlights Taiwan’s growing recognition as a trusted contributor to the global pharmaceutical industry.

04

Nov 2025

ScinoPharm Taiwan 15th in 2025 CSR “Small Giants”

Honored as a 2025 CSR “Small Giants” top 15 company by CommonWealth Magazine.